BenevolentAI Logo

BenevolentAI

Applies artificial intelligence to accelerate drug discovery and development.

BAI | AS

Overview

Corporate Details

ISIN(s):
LU2355630455
LEI:
2221003P54KEDC3P4Z33
Country:
United Kingdom
Address:
4-8 Maple Street, W1T 5HD London

Description

BenevolentAI is a clinical-stage company that specializes in applying artificial intelligence (AI) and machine learning to drug discovery and development. The company utilizes its proprietary technology platform, which is built upon a comprehensive knowledge graph, to analyze vast amounts of complex biomedical information. This platform is designed to generate novel biological insights, identify new therapeutic targets, and accelerate the research and development process for new medicines. By integrating advanced AI with scientific expertise, BenevolentAI aims to decipher complex disease biology and improve the efficiency and success rate of bringing new treatments to patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-12 12:12
BAI EGM Results APPROVED
English 169.9 KB
2025-02-06 07:00
Merger-Delisting and Notice of EGM FINAL APPROVED copy
English 95.2 KB
2024-12-11 13:17
BenevolentAI unveils major strategic overhaul with return to original mission
English 440.5 KB
2024-12-11 07:00
241211_BenevolentAI Statement_FINAL
English 440.5 KB
2024-12-03 13:36
Regulatory Announcement - Issue of Equity and TVR (RSU Settlement) 03122024
English 111.3 KB
2024-10-17 07:00
241017 BenevolentAI_Leadership update_Final
English 384.6 KB
2024-09-23 14:15
Major Shareholding Notification (LINK) - 13 September 2024 rev
English 494.2 KB
2024-09-19 07:00
240919_BAI Interims 24 press release_FINAL
English 468.9 KB
2024-07-30 12:56
PDMR Notification - Dr. Joerg Moeller
English 56.6 KB
2024-07-03 07:00
BAI_LEADERSHIP TEAM CHANGE_FINAL_03.07.2024
English 140.6 KB
2024-05-02 15:30
AGM Results 2 May 2024 FINAL
English 129.2 KB
2024-05-01 12:37
Major Holdings Notification (Annex A) ABG-ODY-BAI LIMITED
English 62.7 KB
2024-04-23 07:00
Business Update 23 April 24 FINAL
English 166.2 KB
2024-04-17 07:00
BAI_Publication of the Revised Agenda for the 2024 AGM_FINAL_17.04.24
English 69.7 KB
2024-04-15 07:00
BAI_PROPOSED CHANGES TO BOARD COMPOSITION _FINAL_15.04.24
English 168.4 KB

Automate Your Workflow. Get a real-time feed of all BenevolentAI filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BenevolentAI

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BenevolentAI via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.